ArticleOrphanet journal of rare diseases2025
A qualitative, mixed-method approach to reaching consensus on function, fatigue, and fatigability outcomes in teens and adults living with spinal muscular atrophy.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpinal muscular atrophy (SMA) is a neuromuscular disease caused by mutations in the survival motor neuron gene, SMN1. Loss of SMN1 function results in deficiency of the SMN protein leading to motor neuron death, muscle wasting, and progressive loss of motor function. Two disease modifying therapies have been approved for teens and adults in the United States, with many more potential treatments in the drug development pipeline. As treatment options for teens and adults with SMA increase, a validated core set of outcome measures is needed to assess motor function, perceived fatigue, and perceived fatigability. The aim of this study was to determine which type of outcome measures best captures changes in disease status in teens and adults with SMA.
resultsIn the first phase of this two-part study, a working group of key opinion leaders in SMA research and clinical care was surveyed using a modified Delphi method. The working group concluded that a patient-reported outcome measure based on activities of daily living (ADLs) would be the best way to capture changes in function, perceived fatigue, and perceived fatigability that are meaningful to clinicians, as well as teens and adults living with SMA. In the second phase of the study, two discussion groups of adults (non-ambulatory or ambulatory) were interviewed for their perspectives about which ADLs are most important to them, and about how perceived fatigue affects their abilities to perform these ADLs. Both discussion groups prioritized ADLs that related to independence and dignity. Non-ambulatory and ambulatory participants also reported that perceived fatigue and fatigability are a major factor in their ability to perform ADLs.
conclusionSMA key opinion leaders and adults with SMA agreed that ADLs would be sensitive and impactful outcomes in the assessment of function, perceived fatigue, and perceived fatigability. The findings of this study form a foundation for reaching consensus around a core set of outcome measures for assessing disease status, perceived fatigue, and perceived fatigability in teens and adults with SMA in the U.S.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.